By
Wandercraft has secured $75 million in Series D funding. The French robotics firm stated that this new investment will facilitate the commercialization of the Eve self-balancing personal exoskeleton by 2026. Additionally, Wandercraft aims to broaden the clinical use of its leading rehabilitation system, Atalante X, and to develop and launch Calvin-40, its latest humanoid model.
"The progress we've made in recent years is remarkable," said Matthieu Masselin, CEO and co-founder of Wandercraft. "We've expanded our global presence, initiated key clinical trials, prepared for the commercialization of Eve, our personal exoskeleton, and formed a significant partnership with Renault Group. This funding enables us to further our mission of revolutionizing how people live, move, and work in rehabilitation, home settings, and soon in industrial environments."
Wandercraft explained that its technology is driven by AI, which has been honed through billions of simulations and tens of millions of real-world steps.
In February, Wandercraft commenced a clinical trial of its personal exoskeleton. This self-balancing exoskeleton is designed to provide upright mobility and walking independence for those with severe mobility challenges, offering the advantages of standing, walking, bending, reaching, and restoring the sensation of natural walking to daily life.
The clinical trial is taking place at the James J. Peters VA Medical Center in the Bronx, NY. Wandercraft announced that another clinical trial will soon begin at the Kessler Institute for Rehabilitation in West Orange, NJ. This study will evaluate the safety and efficacy of the Personal Exoskeleton for individuals with spinal cord injuries (SCI).
During the 2024 Olympics, Wandercraft’s Personal Exoskeleton played a role in carrying the Olympic torch as part of the traditional relay. Kevin Piette, who usually relies on a wheelchair, became the first user of a self-balancing exoskeleton to participate in the torch relay before the Olympics, according to the company.
The funding round saw significant contributions from Renault Group, the PSIM fund, managed on behalf of the French State by Bpifrance as part of the France 2030 plan, Teampact Ventures, and Quadrant Management. Other participants in the Series D round included LBO France, Mutuelles Impact – Managed by XAnge, Cemag Invest, Martagon Capital, and AG2R LA MONDIALE.
